Association of Endocrine Therapy for HR+/ERBB2+ Metastatic Breast Cancer With Survival Outcomes.

ABSTRACT:

Importance

Evidence suggests that patients with human epidermal growth factor receptor 2-positive (ERBB2+ [formerly HER2+]) metastatic breast cancer (MBC) have different clinical characteristics and outcomes according to their hormone receptor (HR) status. The place of endocrine therapy (ET) for patients with HR+/ERBB2+ is still not clearly defined in this setting.

Objective

To evaluate the association of HR status and first-line inclusion of ET with outcomes among patients with ERBB2+ MBC.

Design, setting, and participants

This cohort study was an analysis of clinical data from the French clinical Epidemiological Strategy and Medical Economics (ESME) cohort, including patients with MBC who started treatment between 2008 and 2017. The last date of follow-up was June 1

SUBMITTER: Carausu M 

PROVIDER: S-EPMC9856509 | biostudies-literature | 2022 Dec

REPOSITORIES: biostudies-literature